vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) granted stock options as a material inducement to a new non-executive employee under Nasdaq Listing Rule 5635(c)(4).

The grant covers 2,500 options at an exercise price of $34.30, vesting over four years, with a 10-year term under the 2026 Inducement Plan.

News Market Reaction – VTVT

-0.18%

-0.18% Session close to close

In the Jun 3 session, VTVT declined 0.18%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard equity compensation action: an inducement grant of 2,500 stock ...

Analysis

This announcement details a standard equity compensation action: an inducement grant of 2,500 stock options at an exercise price of $34.30, vesting over four years under the 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Historically, similar grants on April 7 and May 8 had minimal price impact compared with major catalysts like the strong Q1 2026 earnings and licensing updates. Investors monitoring vTv may focus more on Phase 3 CATT1 progress, funding via the ATM tied to the shelf, and upcoming clinical or partnership milestones.

Key Figures

Stock options granted: 2,500 options Exercise price: $34.30 per share Vesting period: 4 years +5 more

8 metrics

Stock options granted 2,500 options Inducement grant to a non-executive employee

Exercise price $34.30 per share Equal to closing price on June 1, 2026

Vesting period 4 years Inducement stock option vesting schedule

Initial cliff vesting 25% Vests on one-year anniversary of vesting start date

Remainder vesting 36 months Remaining options vest quarterly over 36 months

Option term 10 years Term of inducement stock options

Current share price $34.30 Pre-news price level for VTVT

20-day volume avg 43,623 shares Benchmark for today’s trading volume

Historical Context

5 past events · Latest: May 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 13	Earnings and update	Positive	+21.4%	Strong Q1 revenue and profitability plus progress on Phase 3 CATT1 trial.
May 8	Inducement grants	Neutral	-0.7%	Stock option inducement grants to two non-executive employees under 2026 plan.
May 7	Conference participation	Neutral	-2.0%	Announcement of May investor conferences with fireside chats and webcasts.
Apr 7	Inducement grant	Neutral	+0.6%	Inducement stock options to a non-executive employee under Nasdaq Rule 5635(c)(4).
Mar 16	Conference attendance	Neutral	+7.4%	Participation in the 38th Annual ROTH Conference with webcasted fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News and corporate updates have mostly seen price moves that align with the tone of each announcement, with only one notable divergence on a conference-related update.

Recent Company History

Over recent months, vTv has combined clinical and financial progress with routine corporate updates. Q1 2026 results on May 13 showed strong revenue of $36.8M and net income of $24.1M, which coincided with a 21.36% gain. Routine items such as inducement grants under Nasdaq Rule 5635(c)(4) on April 7 and May 8 produced minimal price impact. Conference participation in March and May saw modest mixed reactions. Today’s small inducement grant fits this pattern of low market sensitivity to standard equity-compensation news.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company’s common stock on June 1, 2026. Each option will vest over a 4-year period, with 25% of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to the employee’s continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

What did vTv Therapeutics (VTVT) announce on June 2, 2026?

vTv Therapeutics announced a grant of 2,500 stock options to a non-executive employee as an inducement to employment. According to vTv Therapeutics, the options are issued under Nasdaq Listing Rule 5635(c)(4) and its 2026 Inducement Plan, with a 10-year term.

How many stock options did vTv Therapeutics (VTVT) grant and at what exercise price?

vTv Therapeutics granted 2,500 stock options with an exercise price of $34.30 per share. According to vTv Therapeutics, this price equals the closing price of its common stock on June 1, 2026, aligning the employee’s incentive with the prevailing market value.

What is the vesting schedule for the new vTv Therapeutics (VTVT) stock options?

The 2,500 stock options vest over four years with a one-year cliff. According to vTv Therapeutics, 25% vests on the first anniversary of the vesting commencement date, and the remaining shares vest quarterly over the following 36 months, subject to continued employment.

Under which plan were the new vTv Therapeutics (VTVT) inducement stock options granted?

The stock options were granted under the vTv Therapeutics 2026 Inducement Plan. According to vTv Therapeutics, the options are also governed by a stock option agreement that sets detailed terms and conditions, including vesting, exercise price, and the 10-year option term.

What is the purpose of vTv Therapeutics (VTVT) using Nasdaq Listing Rule 5635(c)(4) for this grant?

The grant is intended as a material inducement to the employment of a non-executive employee. According to vTv Therapeutics, Nasdaq Listing Rule 5635(c)(4) allows equity awards outside shareholder-approved plans specifically to attract new employees in connection with their hiring.